Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone610-640-4202
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$40.43 million
Profitability
Miscellaneous
Employees167
OptionableNot Optionable
Neuronetics (NASDAQ:STIM) Frequently Asked Questions
What is Neuronetics' stock symbol?
Neuronetics trades on the NASDAQ under the ticker symbol "STIM."
How were Neuronetics' earnings last quarter?
Neuronetics Inc (NASDAQ:STIM) issued its earnings results on Tuesday, August, 14th. The company reported ($30.60) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.84) by $29.76. The firm had revenue of $13.25 million for the quarter, compared to analysts' expectations of $12.20 million. View Neuronetics' Earnings History.
When is Neuronetics' next earnings date?
What price target have analysts set for STIM?
5 equities research analysts have issued twelve-month price objectives for Neuronetics' shares. Their forecasts range from $33.00 to $40.00. On average, they anticipate Neuronetics' stock price to reach $36.3333 in the next twelve months. This suggests a possible upside of 102.0% from the stock's current price. View Analyst Price Targets for Neuronetics.
What is the consensus analysts' recommendation for Neuronetics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neuronetics.
What are Wall Street analysts saying about Neuronetics stock?
Here are some recent quotes from research analysts about Neuronetics stock:
- 1. According to Zacks Investment Research, "Neuronetics, Inc. is a commercial-stage medical device company. It focused on designing, developing, and marketing products for patients who suffer from psychiatric disorders. NeuroStar Advanced Therapy System(R), is the transcranial magnetic stimulation treatment for depressive disorder. Neuronetics, Inc. is based in Malvern, United States. " (11/10/2018)
- 2. BTIG Research analysts commented, "$33 PT Q3 revenue topped our estimate on both system sales and treatment sessions. Based on a number of conversations with investors, we sensed there was some concern heading into Q3 on what mix might look like (capital vs. procedure sales) and the overall sequential ramp but we feel results in the quarter confirm our view that sales expansion continues to bear fruit. On that initiative, mgmt added 4 more territories in Q3, fairly consistent with our expectations. Additionally, progress towards Japan reimbursement remains on-track with a decision on reimbursement expected in December and formal commencement in March. Until Japan commercialization begins, mgmt highlighted active preparation efforts as well as the strong level of interest among treating docs. Overall, Q3 results were strong, in our view." (11/7/2018)
Has Neuronetics been receiving favorable news coverage?
Headlines about STIM stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Neuronetics earned a coverage optimism score of 1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the near future.
Who are some of Neuronetics' key competitors?
Some companies that are related to Neuronetics include K2M Group (KTWO), Orthofix Medical (OFIX), Cardiovascular Systems (CSII), Luminex (LMNX), Intersect ENT (XENT), Cryolife (CRY), AngioDynamics (ANGO), Cerus (CERS), SurModics (SRDX), OraSure Technologies (OSUR), Anika Therapeutics (ANIK), LeMaitre Vascular (LMAT), Antares Pharma (ATRS), Orthopediatrics (KIDS) and Inovio Pharmaceuticals (INO).
Who are Neuronetics' key executives?
Neuronetics' management team includes the folowing people:
- Mr. Christopher A. Thatcher, CEO, Pres & Director (Age 54)
- Mr. Peter L. Donato, VP & CFO (Age 49)
- Mr. Gregory Harper, VP of R&D, Operations and Product Devel. (Age 58)
- Mr. Stephen MacKinnon, VP of Sales
- Ms. Cassie Hallberg, VP of Marketing
When did Neuronetics IPO?
(STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.
When did the company's lock-up period expire?
Neuronetics' lock-up period expired on Tuesday, December 25th. Neuronetics had issued 5,500,000 shares in its public offering on June 28th. The total size of the offering was $93,500,000 based on an initial share price of $17.00. Since the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
Who are Neuronetics' major shareholders?
Neuronetics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.48%), Lord Abbett & CO. LLC (2.43%), RTW Investments LP (0.95%), Bellevue Group AG (0.94%), United Services Automobile Association (0.44%) and Geode Capital Management LLC (0.42%). Company insiders that own Neuronetics stock include Daniel Guthrie and Wilfred E Jaeger. View Institutional Ownership Trends for Neuronetics.
Which institutional investors are selling Neuronetics stock?
Which institutional investors are buying Neuronetics stock?
STIM stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Bellevue Group AG, Partner Fund Management L.P., United Services Automobile Association, Millennium Management LLC, Virtus ETF Advisers LLC, Geode Capital Management LLC and GSA Capital Partners LLP. Company insiders that have bought Neuronetics stock in the last two years include Daniel Guthrie and Wilfred E Jaeger. View Insider Buying and Selling for Neuronetics.
How do I buy shares of Neuronetics?
Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neuronetics' stock price today?
One share of STIM stock can currently be purchased for approximately $17.99.
How big of a company is Neuronetics?
Neuronetics has a market capitalization of $316.25 million and generates $40.43 million in revenue each year. Neuronetics employs 167 workers across the globe.
What is Neuronetics' official website?
How can I contact Neuronetics?
Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected]
MarketBeat Community Rating for Neuronetics (NASDAQ STIM)
MarketBeat's community ratings are surveys of what our community members think about Neuronetics and other stocks. Vote "Outperform" if you believe STIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
